Cannabis and Implications for Clinical Dental Practice

Presented by: Dr. José Lança

RCDSO Expiry Date: April 30, 2022

To qualify as a Core Category 1 course, the course certificate must be issued no later than this date.

RCDSO CE Points: 3, Category 1

Points can also be used as Category 2. For further information see our CE Points Page.

Click to close
  • Dr. José Lança MD, PhD

    Assistant Professor of Pharmacology in the Faculty of Dentistry and the Temerty Faculty of Medicine

    Dr. José Lança, MD, PhD is an Assistant Professor of Pharmacology in the Faculty of Dentistry and the Temerty Faculty of Medicine, University of Toronto (UofT). He is also affiliated with the School of Graduate Studies and Centre for the Study of Pain at the UofT. He is also affiliated with the School of Graduate Studies and Centre for the Study of Pain at the U of T. He is a member of several professional organizations, including the American College of Clinical Pharmacology, Society for Neuroscience, and the American Society for Pharmacology and Experimental Therapeutics.

    Dr. Lança has contributed extensively to curriculum development and teaching of pharmacology, therapeutics and interprofessional education.He is the director of several undergraduate and graduate courses in the Faculty of Dentistry and has been the Undergraduate Program Director in the Department of Pharmacology and Toxicology, Faculty of Medicine. He has developed and taught courses and seminars in Continuing Medical and Dental Education, including the American Medical Association, Canadian Dental Association, amongst others.

Current Status
Not Enrolled
Price
50
Get Started

PLEASE NOTE: THIS COURSE CAN NO LONGER BE TAKEN FOR CE POINTS. This course is available now for review by registered users to reprint their Certificates if needed. It has expired and can no longer be taken to achieve CE points or certificates.

Cannabis is a commonly used drug with significant adverse effects and potential for abuse and dependence. Its therapeutic use for specific medical conditions – including neuropathic pain, spasticity in multiple sclerosis, analgesia in cancer patients and prevention of chemotherapy-induced nausea and vomiting – has been approved by Health Canada. Considering the recent legislative changes for the non-medical use of cannabis, it is expected that its use, adverse effects and risks will become more frequent. Therefore, it is important for healthcare professionals to increase awareness of the organization of the endocannabinoid system, cannabinoid exposure and implications for systemic and oral health.

In this presentation Dr. Lança will discuss: (1) the organization of the endocannabinoid system; (2) the mechanisms of action of cannabinoids in medical cannabinoids and in cannabis; (3) the adverse effects of cannabis smoking and ingesting on oral health (e.g., xerostomia, periodontal disease, caries, stomatitis and gingival hyperplasia); (4) the legal framework of non-medical cannabis use; (5) the clinically relevant interactions between cannabis and other compounds, including alcohol, opioids and sympathomimetics; (6) recommendations for prevention and management of non-medical use of cannabis.